You are here: Industry Insights > CSCC

News List

Exicure Provides Interim Results from Ongoing Phase 1b/2 Clinical Trial of Cavrotolimod (AST-008) drugs
August 10, 2021
Exicure, Inc. (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, is providing an update on the Phase 1b/2 clinical trial of cavrotolimod (AST-008) (NCT03684785).
FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma americanpharmaceuticalreview
July 03, 2020
The Food and Drug Administration (FDA) approved pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.
ASTRO Issues Recs for Radiation Tx of Basal, Squamous Cell Carcinoma drugs
December 25, 2019
In an executive summary of an American Society for Radiation Oncology clinical practice guideline, published online in Practical Radiation Oncology, recommendations are presented for the use of radiation therapy (RT) for basal cell carcinoma (BCC) and ...
Libtayo approved for CSCC in the EU, including through the NHS in the UK pharmaceutical-technology
July 04, 2019
Sanofi and Regeneron have announced that the European Commission (EC) has granted conditional approval to Libtayo (cemiplimab) for patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), a form of skin cancer, who cannot be
Health Canada issues Notice of Compliance with Conditions (NOC/c) for Libtayo (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) firstwordpharma
April 12, 2019
CSCC is the second most common skin cancer in Canadai.
US priority review for Sanofi, Regeneron’s cemiplimab pharmatimes
May 03, 2018
US regulators are undertaking a priority review of Sanofi and Regeneron’s cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC)...
Regeneron and Sanofi receive FDA’s breakthrough therapy status for CSCC treatment with cemiplimab pharmaceufical-technology
September 12, 2017
The FDA status will enable the companies to use cemiplimab for the treatment of adults with metastatic CSCC or adults with locally advanced and unresectable CSCC.
FDA grants Breakthrough designation to Cemiplimab for CSCC europeanpharmaceuticalreview
September 11, 2017
Cemiplimab receives FDA Breakthrough Therapy Designation for advanced cutaneous squamous cell carcinoma…